Cytokinetics, Inc. operates as a specialized biopharmaceutical company focused on the mechanics of muscle biology. The company develops small molecule therapeutics that impact how muscle fibers contract, aiming to treat cardiovascular and neuromuscular diseases. Its key clinical and commercial pipeline includes cardiac myosin inhibitors like aficamten (marketed as MYQORZO) for hypertrophic cardiomyopathy, as well as treatments for heart failure and rare neuromuscular conditions. Operating primarily in the United States, Cytokinetics partners with larger pharmaceutical companies for global commercialization, licensing, and research. The company generates revenue through technology transfers, milestone payments, and direct product sales.
